PTO/SB/21 (02-04)

	Approved for use through 07/31/2006. ONE 0651-003
c	Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork F	Reduction Act of 1895, no pers		tion of information unless it displays a valid OMB control number.					
	/O'\	Application Number	10/718,526					
TRANS	MITTAL	Ailing Date	November 23, 2003					
FC	DRM ( APR 1 4 201	First Named Inventor	TAM, Cherk Shing					
(to be used for all corresp	pondence atter initial filing)	Art Unit						
	TRADE	Examiner Name						
Total Number of Pages in	This Submission 9	Attorney Docket Number	32404-2054					
<u> </u>	ENCLOSURES (Check all that apply)							
Fee Transmittal F		Drawing(s) Licensing-related Papers	After Allowance communication to Group  Appeal Communication to Board of Appeals and Interferences					
Amendment/Reply After Final Affidavits/c		Petition  Petition to Convert to a Provisional Application  Power of Corney, Revocation	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter					
Extension of Time	Request	Change of Correspondence Ad Terminal Disclaimer	Other Enclosure(s) (please Identify below):					
Express Abandon	ment Request	Request for Refund	•					
Information Disclo	sure Statement	CD, Number of CD(s)	Copies of Non-Patent References  L foreign galent  documents.					
Certified Copy of Document(s)	Priority		documents.					
Response to Miss		marks						
	e to Missing Parts CFR 1.52 or 1.53							
· · · · · · · · · · · · · · · · · · ·								
Firm		OF APPLICANT, ATTORN						
or Individual name	2. Hunt (Regn. No. 36,4	424) TORYS LLP - Customer	No. 33721					
Signature Signature	Dela Klinit		-					
Date Smil (2/04								
I hereby certify that this c sufficient postage as first the date shown below.	I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.							
Typed or printed name								
Signature			Date					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction A

Substitute for form 1449/PTO

Sheet | 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of |8

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/718,526			
Filing Date	November 23, 2003			
First Named Inventor	TAM, Cherk Shing			
Art Unit				
Examiner Name				
Attorney Docket Number	32404-2054			

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	Number-Kind Code <sup>2 (if known)</sup>	0/4000	NAME OF THE PARTY	1.32.00
	ļ .	<sup>US-</sup> 4,320,118 A	3/1982	White et al.	
		<sup>US-</sup> 4,877,864 A	10/1989	Wang et al.	
		<sup>US-</sup> 4,897,348 A	1/1990	Johnston et al.	
,		<sup>US-</sup> 5,011,691 A	4/1991	Oppermann et al.	
		<sup>US-</sup> 5,024,841 A	6/1991	Chu et al.	
		<sup>US-</sup> 5,264,214 A	11/1993	Rhee et al.	
		<sup>US-</sup> 5,304,542 A	4/1994	Tatakis	
		<sup>US-</sup> 5,354,557 A	10/1994	Oppermann et al.	
		<sup>US-</sup> 5,461,034 A	10/1995	Rodan et al.	
		<sup>US-</sup> 5,470,831 A	11/1995	Whitman et al.	
		<sup>US-</sup> 5,470,911 A	11/1995	Rhee et al.	
		<sup>US-</sup> 5,504,190 A	4/1996	Houghton et al.	
		<sup>US-</sup> 5,578,569 A	11/1996	Tam	
		<sup>US-</sup> 5,643,549 A	7/1997	Rhodes	
		US- 5,661,127 A	8/1997	Bhatnagar et al.	
		<sup>US-</sup> 5,776,892 A	7/1998	Counts et al.	
		<sup>US-</sup> 5,786,327 A	7/1998	Tam	
		<sup>US-</sup> 5,792,664 A	8/1998	Chait et al.	
		<sup>US-</sup> 5,880,094 A	3/1999	Tam	

	-	FORE	IGN PATENT DOCU	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sub>6</sub>
		EP 0451867	10/1991			
		EP 0499242	8/1992			
		EP 0504938	9/1992			
		GB 2231872	7/1992			
		WO 90/00060	1/1990			
		WO 9006321	6/1990		,	

Examiner	Date	
Signature	Considered	
. •		l

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

32404-2054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known

Application Number 10/718,526

Filing Date November 23, 2003

First Named Inventor TAM, Cherk Shing

Art Unit

Examiner Name

of |8

Sheet

Attorney Docket Number

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		<sup>US-</sup> 6,117,839 A	9/2000		
		<sup>US-</sup> 6,274,702 B1	8/2001		
		us- 6,352,973 B1	3/2002		
		US-			
		US-			
-		US-			
	<del></del>	US-			
		US-			
	<del> </del> -	US-			
		US-			
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	

		FORE	IGN PATENT DOCU	MENTS	_	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
		WO 91/11515	8/1991			
		WO 92/14481	9/1992			
		WO 94/05309	3/1994			
		WO 94/20615	9/1994			
		WO 95/28172	10/1995			
		WO 97/12036	4/1997			

Examiner	Date	
Signature	Considered	
-		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
Cabsina	10 10 10 11			Application Number	10/718,526	
INF	ORMATION	DIS	CLOSURE	Filing Date	November 23, 2003	
STATEMENT BY APPLICANT				First Named Inventor	TAM, Cherk Shing	
	<i>(</i> 11	-4		Art Unit		
	(Use as many she	ets as n	ecessary)	Examiner Name		
Sheet	3	of	8	Attorney Docket Number	32404-2054	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DART ET AL. Transforming growth factors from a human tumor cell: characterization of weight transforming growth factor alpha. Biochemistry, (Oct. 8, 1985) 24 (21) 5925-31.	
		BOWIE ET AL. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science. (Mar. 16, 1990) 247 (4948) 1306-10.	
		NGO ET AL., The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495.	
		EHLERT ET AL. J. Biol Chem. Mar. 17, 1995;270(11):6338-44, Oct. 1985.	
		ALFRED WALZ AND MARCO BAGGIOLINI: A Novel Cleavage Product of B-Throm Human Neutrophils, vol. 159, No. 3, 1989; Mar 31, 1989; pp. 969-975 Theodor-Kocher-Institut, Universi	
		Selye, "On the Stimulation of New Bone-Formation" Endocrinology 16: 547-558 (1933).	
		AITKEN ET AL. "Primary Hyperparathyroidism with Osteosclerosis" Am. J. Med. 37:813-820 (Nov. 1964).	
		Kalu et al., "Parathyroid Hormone and Experimental" Lancet 1363-1366 (Jun. 1970).	
		KLEIN ET AL., "Prostaglandins: Simulation of Bone Resorption" Endocrinology 86: 1436-14 1440 (Jun. 1970).	
		CONNOR ET AL., "Generalized Osteosclerosis in Primary" Trans Am. Clin. Climato. ASsoc. 85: 185-201 (1973).	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	te for form 1449/PTO			Complete if Known		
Jubstitu	te 101 101111 1443/F 10			Application Number	10/718,526	
INF	ORMATION	DIS	SCLOSURE	Filing Date	November 23, 2003	
STATEMENT BY APPLICANT				First Named Inventor	TAM, Cherk Shing	
	(llee ee menu abo			Art Unit		
(Use as many sheets as necessary)				Examiner Name		
Sheet	4	of	8	Attorney Docket Number	32404-2054	

	0''	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GENANT, "Osteosclerosis in Primary Hyperparthyroidism" Am. J. Med. 59: 104-113 (Jul. 1975).	
		RUDINGER ET AL. Peptide Hormones. Parsons, eds., University Park Press, Baltimore, pp. 1-7, 1976.	
		TAM ET AL., "Bone Apposition Rate as an Index of" Metabolism 27(2): 143-150 (Feb. 1978).	
		BEGG ET AL., "Complete Covalent Structure of Human.beta-Thromboglobulin", Structure of .beta-Thromboglobulin, vol. 17, No. 9, 1978, pp. 1739-1744.	
		SCHULZ ET AL., Principles of Protein Structure, Springer-Verlag, New York, pp. 14-16, 1979.	
		MARKS ET AL., "The Hematogenous Origin of Osteoclasts: Experimental" Am. J. Anat 161:1-10 (1981).	
		CHEN, "Glucocorticoid Regulation of 1.25(OH)2-Vitamin D3" J. Bio. Chem. 257(22):13564-13569 (Nov. 1982).	
		PARFITT, "The Coupling of Bone Formation to Bone" Metab. Bone Dis & Rel. Res. 4:1-6 (1982).	
		TAM ET AL., "Parathyroid Hormone Stimulates the Bone" Endocrinology 110(2):506-512 (1982).	
		C.W.CASTOR ET AL., "Structural and Biological Characteristics of TissuePlatelet-3 derived Growth Factor", Proc. Natl. Acad. Sci. USA, vol. 80, Fed. 1983, pp. 765-769.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	ite for form 1449/PTO				Complete if Known
Oubstitu	ite 10/10/11/1445/1170			Application Number	10/718,526
INF	ORMATION	DIS	CLOSURE	Filing Date	November 23, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	TAM, Cherk Shing
	44	4		Art Unit	
(Use as many sheets as necessary)				Examiner Name	
Sheet	5	of	8	Attorney Docket Number	32404-2054

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		CHYUN, "Stimulation of Bone Formation by Prostaglandin E2" Prostaglandins J. 27(1):97-103 (Jan. 1984).	
		CANALIS, "Effect of Growth Factors on Bone Cell" Clin. Orthop. & Rel. Res. 246-263 (1985).	
		OWEN, "Lineage of Osteogenic Cells and Their" Bone & Mineral Res. 3 (1):1-25(1985).	
		SUNDELIN ET AL., "The Primary Structure of Rabbit and Rat Prealbumin" J. Biol. Chem. 260(10):6481-6487 (May 1985).	
		GEORGE ET AL., Macromolecular Sequencing and Synthesis: Selected Methods and Applications, Schlesinger, ed., Alan R. Liss Inc., New York, pp. 127-149, 1988."	
		CASTOR ET AL., "Connective Tissue Activation-BiologiallyFrom Human Platelets", Biochemical and Biophysical Research Communications, vol. 163, No. 2, 1989, pp. 1071-1078.	
		NODA ET AL. In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology, (Jun. 1989) 124(g) 2991-4.	
		TAM, "The Pathogenesis of Metabolic Bone Disease" CRC Press, Boca Raton 2: 19-31 (1989).	

Examiner	 Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions device the chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number

	ite for form 1449/PTO			C required to respond to a concessor	Complete if Known			
Substitu	ite ioi ioiiii 1445/F10			Application Number	10/718,526			
INF	ORMATION	DIS	CLOSURE	Filing Date	November 23, 2003			
STATEMENT BY APPLICANT				First Named Inventor	TAM, Cherk Shing			
	(llee ee many abo	ata aa n	onaccand	Art Unit				
<u> </u>	(Use as many she	ets as n	ecessary)	Examiner Name				
Sheet	6	of	8	Attorney Docket Number	32404-2054	$\overline{\mathcal{I}}$		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		WALZ ET AL., "Generation of the Neutrophil-ActivatingIssue-3 Activating Peptide III Through Monocyte Proteases", Journal of Med., vol. 171, Feb. 1990, pp. 449-454.	
		WOZNEY ET AL., J. Cell. Sci. Suppl. 13:149-156 (1990).	
		CASTOR ET AL., "Connective Tissue Activation", Arthritis & Rheumatism, vol. 35, No. 7, Jul. 1992, pp. 783-793.	
		Roodman, "Perspectives: Interleukin-6: an Osteotropic Factor?" J. Bone & Mineral Res. 7(5):475-478 (1992).	
		VAUGHAN ET AL., Identification and Characterization of the Insertion Element IS1070 from Leuconostoc lactis NZ6009, Elzevier Science B.V. pp. 95-100 (1995).	<u>-</u>
		NAVAB ET AL., "Rat Plasma Prealbumin" J. Biol. Chem. 252:5100-5106 (Jul. 1997).	
		VAUGHAN ET AL., U17353, Leuconostoc lactis insertium sequence IS1070: Is1070 putative transposase (tnp) gene, complete eds. Sep. 13, 1995.	
		STEDMAN'S MEDICAL DICTIONARY, 27TH edition Medical Economics Company, Inc. 2000.	
		ABSTRACT-WO 92/10515, PHARMA Bissendof peptide GMBH, Derivatives of the Human Parathormone Fragment (1-37) in the Amide or Ethylamide Form as Active Substance, Jun. 25, 1992.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 23313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	Substitute for form 1449/PTO				Complete if Known		
Cubstitu	10 10 10 11 1440 110			Application Number	10/718,526		
INF	ORMATION	I DIS	SCLOSURE	Filing Date	November 24, 2003		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	TAM, Cherk Shing		
	(Han as many she		200055284	Art Unit			
(Use as many sheets as necessary)				Examiner Name			
Sheet	7	of	8	Attorney Docket Number	32404-2054		

	1	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ABSTRACT-WO 92/15615, Chugai Seiyaku Kabushiki Kaisha, Serum Calcium Depressing Factor, Stp. 17, 1992.	
		COCCIA ET AL. "Successful Bone-Marrow Transplantation" New England Journal of Medicine 302(13) 701-708 (1980).	
		CANALIS, "Interleukin-1 has Independ Effects on Deoxribonucleic" Endocrinology 118(1):74-81 (1986).	
		CENTRELLA ET AL., "Transforming and Non-Transforming Growth Factors are" Proc. Natl. Acad. Sci USA 82:7335-7339 (Nov. 1985).	
		CANALIS, "Effect of Insulin-like Growth Factor I on DNA" J. Clin. Invest. 66:709-719 (Oct. 1980).	
		TASHJIAN ET AL. "a and B Human Transforming Growth Factors" Proc. Natl. Acad. Sci. USA82:4535-4538 (Jul., 1985).	
		MAJUMDAR ET AL. "Characterization of the Human B-thromboglobulin" J. Bio. Chem 266(9):5785-5787 (Mar. 1991).	
		·	
		INTERNATIONAL SEARCH REPORT issued by European Patent Office on international patent application No. PCT/CA96/00653, published Jun. 5, 1997.	
		INTERNATIONAL SEARCH REPORT issued by European Patent Office on international patent aplication No. PCT/CA00/00031, published Jul. 20, 2000.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.